The Efficacy and Safety of Azovudine in the Treatment of COVID-19

Inclusion Criteria: 1. Over 18 years old; 2. Respiratory tract samples (nasopharynx, oropharynx, lower respiratory tract \[such as sputum\]) collected within 96 hours before enrollment were confirmed to be SARS CoV-2 positive by RT-PCR virus molecular amplification; 3. At least one symptom or sign of COVID-19 (symptoms and signs related to COVID-19, including cough, expectoration, dyspnea, fever, chills, fatigue, muscle soreness, diarrhea, headache, sore throat, nasal congestion, runny nose, etc.); 4. Participants who meet one or more of the following requirements: from the first COVID-19 symptom to the first medication ≤ 5 days; 5. Agree to observe contraceptive measures during the clinical trial; 6. Participants who understand and agree to follow the planned research procedures; 7. Provide follow-up information during the study; 8. Understand the study and be willing to sign the informed consent form. Exclusion Criteria: 1. Those who are known to be allergic to any component of the intervention preparation used in the test; 2. Patients with abnormal liver function test (alanine aminotransferase and /or glutamic oxaloacetic aminotransferase exceed the upper limit of normal value by 3 times, or total bilirubin exceeds the upper limit of normal value by 2 times); 3. Patients with a known history of liver disease (cirrhosis with ChildPugh grade B and C); 4. Congestive heart failure within 6 months (NYHA ¾ Grade), patients with untreated symptomatic arrhythmia or myocardial infarction history; 5. Individuals with malabsorption syndrome or other diseases affecting gastrointestinal absorption, and patients who need intravenous nutrition or cannot take orally or through nasogastric tube; 6. Participants who have received other SARS CoV-2 monoclonal antibody therapy or antiviral therapy (including research therapy); 7. Participants who received COVID-19 convalescent plasma therapy; 8. Patients receiving anti HIV treatment; 9. Participants who also participate in any other type of medical research or are considered to be scientifically or medically incompatible with this research; 10. Participants who have participated in the intervention clinical research in the past 30 days should pass 5 half lives or 30 days, whichever is longer, if the previous research intervention has a longer half life. 11. Researchers believe that the test will endanger any health and safety of participants; 12. Women who are pregnant, nursing or planning to be pregnant during the study period or men whose partners plan to be pregnant during the study period; 13. Unable to provide informed consent.Contacts and Locations.